Biotech Values

[iwfal]

AMPE’s post hoc spin in DME trial is as silly as some of the stuff you joked about

Accounting for odds:

1) It's a post hoc - strike 1

2) It's implies a U-shaped dose response which is rare indeed (i.e. improbable) - strike 2

3) Even if it is, in fact, efficacious with a U-shaped dose response, it is much more difficult to run trials that will succeed - strike 3.

PS FWIW my subgroups aren't intended, per se, to be funny. Just to make the fallacy of subgroup logic clear.